GSK Licenses Liver Disease Drug to Italy's Alfasigma for up to $690 Million

GSK licenses liver disease drug to Italy's Alfasigma for up to $690 million

Alfasigma licenses liver drug from GSK in $590m deal

With an FDA verdict looming, GSK has signed an eleventh-hour deal to give Alfasigma rights to its primary biliary cholangitis therapy linerixibat.

Alfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decision - European Biotechnology Magazine

Italian drugmaker Alfasigma has struck a licensing deal to take over global rights to linerixibat, GSK’s late-stage candidate for cholestatic pruritus in primary biliary cholangitis (PBC), in a transaction that could be worth up to $690 million to the British pharma group. Under the agreement, GSK will receive $300 million upfront, with additional regulatory and commercial milestones plus tiered double-digit royalties on worldwide sales. The pos…

GSK sells liver disease drug candidate to Alfasigma for $690m - Pharmaceutical Technology

GSK’s linerixibat is currently under regulatory review in the US, Europe, and China, amongst other regions.

GSK licenses pill for liver disease itch to Alfasigma for $300M upfront

GSK is licensing out the liver disease drug linerixibat to the Italian pharma Alfasigma for $300 million upfront, weeks ahead of the pill's March 24 PDUFA date. The drug, which is ...